Navigation Links
Peregrine Pharmaceuticals Awarded Two New U.S. Patents Broadening Its Targeted Anti-Phospholipid Patent Portfolio
Date:6/16/2008

- New Claims Cover Anti-Viral Applications of Novel Targeted Agents Under

the Company's Anti-Phospholipid Technology Platform - - Anti-Viral Potential of These New Agents Supported by Recent Studies

Presented at American Association of Immunologists Annual Meeting -

TUSTIN, Calif., June 16 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM), a clinical stage biopharmaceutical company developing monoclonal antibodies for the treatment of cancer and hepatitis C virus infection (HCV), today reported the issuance of two U.S. patents that significantly broaden the company's intellectual property leadership in the field of targeted anti-aminophospholipid agents. The new patents grant Peregrine broad anti-viral method claims using a range of phosphatidylethanolamine (PE) binding agents, including PE-binding peptides attached to anti-viral agents as well as those conjugated to antibodies or other substances.

"These are significant patents for Peregrine that substantially expand our intellectual property portfolio in the field of aminophospholipid-targeting agents," said Dr. Shelley Fussey, vice president of intellectual property at Peregrine. "These anti-PE agents appear to have anti-viral properties similar to the anti-phosphatidylserine (PS) monoclonal antibody bavituximab that we currently are testing in clinical trials in HCV patients and in preclinical studies for HIV and other viral infections. We are especially pleased at the breadth of the issued claims, which provide Peregrine with U.S. patent coverage for methods of combating all relevant viruses using the claimed anti-PE peptide conjugates, either used alone or in combination with other anti-viral drugs. As peptide conjugates, anti-PE agents may be well-suited for use in some of these broad anti-viral applications."

The science underlying the two new patents was presented in April 2008 at the 95th Annual Meeting of the American Association of Immunologists by Dr. Melina Soares of the University of Texas Southwestern Medical Center.* She presented data showing that similar to PS, the target for Peregrine's bavituximab program, the aminophospholipid PE is normally located on the inside of cell membranes, but becomes exposed on the external surface of enveloped viruses and virus-infected cells. Using a biotin-conjugated form of the peptide drug duramycin, which is known to bind to PE, Dr. Soares and her colleagues demonstrated that exposed PE could serve as a broad-spectrum target for anti-viral therapy. Specifically, they showed that duramycin linked to biotin neutralized multiple enveloped viruses and that it showed therapeutic efficacy in a lethal mouse model of cytomegalovirus.

U.S. Patent #7,378,386 issued on May 27, 2008 and U.S. Patent #7,384,909 issued on June 10, 2008.

*M. Melina Soares, Susan Mims, Gustavo Barbero, Shuzhen Li and Philip E. Thorpe, "Anti-Viral Effects of Phosphatidylethanolamine-Targeting Agents", American Association of Immunologists Annual Meeting, San Diego, California, April 7, 2008.

About Peregrine Pharmaceuticals

Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of innovative product candidates in clinical trials for the treatment of cancer and hepatitis C virus (HCV) infection. The company is pursuing three separate clinical programs in cancer and HCV infection with its lead product candidates bavituximab and Cotara(R). Peregrine also has in-house manufacturing capabilities through its wholly owned subsidiary Avid Bioservices, Inc. (http://www.avidbio.com), which provides development and bio-manufacturing services for both Peregrine and outside customers. Additional information about Peregrine can be found at http://www.peregrineinc.com.

Safe Harbor Statement: Statements in this press release which are not purely historical, including statements regarding Peregrine Pharmaceuticals' intentions, hopes, beliefs, expectations, representations, projections, plans or predictions of the future are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Factors that could cause actual results to differ materially include, but are not limited to, uncertainties associated with completing preclinical and clinical trials for our technologies; the early stage of product development; the significant costs to develop our products as all of our products are currently in development, preclinical studies or clinical trials; obtaining additional financing to support our operations and the development of our products; obtaining regulatory approval for our technologies; anticipated timing of regulatory filings and the potential success in gaining regulatory approval and complying with governmental regulations applicable to our business. Our business could be affected by a number of other factors, including the risk factors listed from time to time in the company's SEC reports including, but not limited to, the annual report on Form 10-K for the year ended April 30, 2007 and the quarterly report on Form 10-Q for the quarter ended January 31, 2008. The company cautions investors not to place undue reliance on the forward-looking statements contained in this press release. Peregrine Pharmaceuticals, Inc. disclaims any obligation, and does not undertake to update or revise any forward-looking statements in this press release.

Contacts:

GendeLLindheim BioCom Partners

Investors Media

info@peregrineinc.com Barbara Lindheim

(800) 987-8256 (212) 918-4650


'/>"/>
SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Data To Be Presented at ASCO Supports Potential of Peregrines Cotara(R) for the Treatment of Brain Cancer
2. Peregrine Pharmaceuticals Completes Patient Enrollment in First Stage of Bavituximab Phase II Breast Cancer Trial
3. Peregrine Researchers Present New Preclinical Data at AACR Annual Meeting Confirming Unique Anti-Tumor Mechanism of Bavituximab
4. Preclinical Study Presented at AACR Annual Meeting Shows Peregrines Anti-PS Immunocytokines Can Generate Protective Immune Responses in a Highly Aggressive Breast Cancer Model
5. Preclinical Study Presented at AACR Annual Meeting Shows Broad Anti-Cancer Potential of Peregrines anti-PS Vascular Targeting Antibodies
6. Clinical Experience With Peregrines Anti-Cancer Agent Bavituximab Presented at Leading Symposium on Anti-Angiogenic Agents
7. Peregrine Pharmaceuticals Opens Enrollment in Phase II Clinical Trial of Bavituximab in Patients with Advanced Breast Cancer
8. Peregrine Pharmaceuticals Receives Approval to Conduct a Second Phase II Trial of Bavituximab in Patients With Advanced Breast Cancer
9. Peregrine Pharmaceuticals Receives Approval to Conduct a Phase II Trial of Bavituximab in Patients With Non-Small Cell Lung Cancer
10. Peregrine Announces Addition of The Johns Hopkins Hospital as Study Site for Bavituximab Trial in HCV Patients Co-Infected With HIV
11. New Data Confirms That a Selective, Fully Human Anti-VEGF Antibody Being Developed by Peregrine is as Effective as Avastin(R) in Preclinical Cancer Models
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2017)... Sept. 18, 2017 EpiVax, Inc. ... bioinformatics and immune engineering, today announced a ... A (H7N9) vaccine. ... seasonal influenza and presents a challenge for ... exposure to be effective. Using state-of-the-art bioinformatics and ...
(Date:9/12/2017)... NEW YORK , Sept. 12, 2017   EcoVadis , ... supply chains, has published the first annual edition of its Global CSR ... than 20,400 companies evaluated by EcoVadis, based on Scorecard Ratings that analyzed ... ... & Performance Index ...
(Date:9/12/2017)...  ValGenesis Inc., the global leader in Enterprise ... announce the appointment of Dr. Ajaz Hussain ... Directors and Chairman of Advisory Board beginning September ... to manage their entire validation lifecycle process electronically ... process. Furthermore, ValGenesis VLMS enables rigorous compliance, helps ...
Breaking Medicine Technology:
(Date:9/20/2017)... ... September 20, 2017 , ... “Psalms of Humidity”: is ... of mind and move the readers one step closer to God. “Psalms of Humidity” ... that his mistakes that have been made within his life are the very same ...
(Date:9/19/2017)... ... September 19, 2017 , ... ... jiu-jitsu community have raised more than $15,000 in just a couple of weeks ... submission grappling matches and world-class instructor seminars, organizers expect to double those initial ...
(Date:9/19/2017)... ... 2017 , ... Peter Chandonait, Abt Associates Principal Scientist and ... Africa Indoor Residual Spraying (AIRS) Project , has been named the Grand Prize ... Award, a USAID Catalyst Award, recognizes USAID staff and implementing partners who have ...
(Date:9/19/2017)... ... , ... MelaKids, a Laredo-based company, has introduced a new concept for children’s ... gives us a full supply of melanin – in the back of the eye ... pigment; however, around the age of thirty, we develop a yellow-brown pigment in the ...
(Date:9/19/2017)... RESTON, Va (PRWEB) , ... September 19, 2017 , ... ... on the use of health IT to create efficiencies in healthcare information exchange and ... announced the release of their latest industry white paper, entitled Barriers to Adoption ...
Breaking Medicine News(10 mins):